SOTIO is a biotechnology company developing new Active Cellular Immunotherapy (“ACI”) using a patient’s activated dendritic cells for the treatment of cancer and autoimmune diseases, which we call “DCVAC”. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies. Pre-eminent scientists from the Czech Republic work at SOTIO’s world-class research facility in Prague aiming to better understand the role of dendritic cells in the therapeutic activation of the body’s immune response and to verify the efficacy and safety of DCVAC in clinical trials.
DCVAC was initially developed by scientists at the Department of Immunology of the 2nd Medical School of Charles University and with the Motol University Hospital, both based in Prague. Today, members of SOTIO’s Expert Committee – including leading clinicians in the field of immunotherapy and genitourinary cancer care – contribute to the preparation and implementation of SOTIO’s clinical development program.
SOTIO has an active presence in Europe, the United States, Russia and China. Manufacturing capabilities are being developed to cover these geographies. Due to its central location, SOTIO’s GMP production facility in Prague manufactures DCVAC for SOTIO’s clinical programs in Europe and Russia. The company has also constructed a dedicated production facility in Beijing, China.
SOTIO’s philosophy of research into ACI for the treatment of cancer and autoimmune diseases is based on the following:
- Use of SOTIO’s proprietary “ACI-MAP” (Active Cellular Immunotherapy Multiple Antigen Presentation) technology. SOTIO’s proprietary ACI-MAP method uses the patient’s own dendritic cells, activated by a broad range of tumor antigens, to induce a complex immune response.
- Concept of combination therapy. While SOTIO studies the efficacy and safety as a stand-alone treatment for patients with early stage cancers, we are also investigating ACI-MAP to treat patients in more advanced stages of cancer, by combining DCVAC with other standard of care treatments, coordinated in a synergistic way to control disease progression.
- Long-term boosting of the immune response. SOTIO’s ACI uses one apheresis to produce multiple doses of DCVAC, administered to a patient at various intervals (e.g. every 3 - 6 weeks) over an extended period of time, often for more than one year. SOTIO is exploring the concept that patients can have their immune specific control stimulated through long-term continuous immune boosting with DCVAC manufactured from one leukapheresis.
The combination of the above-mentioned principles is being tested in current studies and is expected to result in more effective ACI for patients who have limited treatment options.
SOTIO is currently focused on developing a new ACI for the treatment of prostate cancer, referred to as DCVAC/PCa. Phase II clinical trials of DCVAC/PCa, involving a few hundred patients with prostate cancer at various stages are ongoing, as preliminary results from phase I clinical trials supported continuing investigations.
In May 2014 SOTIO initiated VIABLE, a global phase III clinical trial studying DCVAC/PCa as an add-on therapy to 1st line standard of care chemotherapy in men with metastatic castration resistant prostate cancer (mCRPC). SOTIO’s aim is to enrol a total of about 1,170 prostate cancer patients in Europe and the United States.
In October 2013, SOTIO launched three phase II clinical trials to assess the use of DCVAC combined with the standard of care in patients with epithelial ovarian cancer (referred to as DCVAC/OvCa). These clinical trials take place at medical centers in the Czech Republic, Germany and Poland and include patients in selected stages of their disease and with specific reaction to the current standard treatment.
The company is also undertaking early-stage research geared towards the use of an ACI in the treatment of lung cancer (DCVAC/LuCa) and plans to launch phase I clinical trials soon.
Part of PPF Group
SOTIO is a part of PPF Group, one of the largest investment groups in Central and Eastern Europe (for further information please see www.ppf.eu).